Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials

References

• Unaids.org [Internet]. Geneva (CH): UNAIDS. 2020 [ cited 2021 Mar 27]. Seizing the moment. Available from: https://www.unaids.org/en/resources/documents/2020/global-aids-report
   Google Scholar
• Marcus JL, Increased overall life expectancy but not comorbidity-free years for people with HIV. CROI 2020, Boston: Massachusetts; 8-11 Mar 2020, 2020; Virtual.
   Google Scholar
• Unaids.org [Internet]. Geneva (CH).2020 [ cited 2021 Mar 27]. Global HIV & AIDS statistics - 2020 fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Anokye R, Acheampong E, Budu-Ainooson A, et al. Knowledge of HIV/AIDS among older adults (50 years and above) in a peri-urban setting: a descriptive cross-sectional study. BMC Geriatr. 2019;19(1):1–8.
   PubMed Web of Science ®Google Scholar
• OurWorldInData.org [Internet] Our world in data. 2019 [ cited 2021 Mar 27]. Roser M, Ritchie H. HIV/AIDS - Our World in Data. Available from: https://ourworldindata.org/hiv-aids
   Google Scholar
• Unaids.org [Internet] Geneva (CH): UNAIDS. 2020 [ cited 2021 Mar 28]. The AIDS response in the 2030 agenda for sustainable development: joint work, shared gains. Available from: https://www.unaids.org/en/AIDS_SDGs.
   Google Scholar
• Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;2019(27):111–121.
   Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.
   PubMed Web of Science ®Google Scholar
• Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17-F24.
   Google Scholar
• Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using québec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–253.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191–1201.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Sassa KN, O’Connor JR, et al. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6(10):1–4.
   Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381(9):803–815.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–1214.
   PubMed Web of Science ®Google Scholar
• Shah BM, Schafer JJ, Desimone JA. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014;34(5):506–520.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: a Review in HIV-1 Infection. Drugs. 2018;78(17):1817–1828.
   PubMed Web of Science ®Google Scholar
• Em G, Hullsiek KH, Telzak EE, et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS. 2010;24(3):395–403.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Perelas A, Wanke C, et al. The HIV-1/HAART associated metabolic syndrome - Novel adipokines, molecular associations and therapeutic implications. J Infect. 2010;61(2):101–113.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-Week analysis. AIDS. 2009;23(13):1679–1688.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21(1):41–46.
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Lundgren J. HIV therapies and the kidney: some good, some not so good? Curr HIV/AIDS Rep. 2012;9(2):111–120.
   PubMed Web of Science ®Google Scholar
• Anta L, Llibre JM, Poveda E, et al. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS. 2013;27(1):81–85.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55–65.
   PubMed Web of Science ®Google Scholar
• Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–271.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Folkers GK, Lane HC. Harrison, Principles of Internal Medicine. 20th. New York: Mc Graw Hill Education; 2018. editor.
   Google Scholar
• Ema.europa.eu [Internet]. European medicines agency; 2020 [ cited 2021 Feb 6. CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment report. Available from: https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp
   Google Scholar
• Fda.gov [Internet]. US Food and drug administration. 2020 [ cited 2021 Feb 6]. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection
   Google Scholar
• Orkin C. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020;382:1124–1135.
   PubMed Web of Science ®Google Scholar
• Orkin C. Long Acting Cabotegravir + Rilpivirine for HIV Treatment - week 96 FLAIR trial. Abstract presented at: antiretroviral Therapy: outcomes in Treatment-naives Patients. CROI. Boston: Massachusetts; 2020 March 8–11.
   Google Scholar
• Swindells S, J-f A-V, Richmond GJ, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020;382(12):1112–1123.
   PubMed Web of Science ®Google Scholar
• Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396(10267):1994–2005.
   PubMed Web of Science ®Google Scholar
• Jaeger H. Week 96 Efficacy and Safety of Cabotegravir + Rilpivirine Every 2 Months: ATLAS-2M. Abstract presented at: long-Acting Therapy: the Time has come. CROI. Boston: Massachusetts; 2020 March 8–11.
   Google Scholar
• Swindells S, Lutz T, Van ZL, et al. Cabotegravir + Rilpivirine Long-Acting As Hiv-1 Maintenance Therapy : atlas Week 96 Results. HIV Drug Ther Glas. 2020;382:2020.
   Google Scholar
• Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020;382(13):1232–1243.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740–e751.
   PubMed Web of Science ®Google Scholar
• ClinicalInfo.hiv.org [Internet]. Rockville (MD): Albuvirtide; [ cited 2021 Mar 27]. Available from: https://clinicalinfo.hiv.gov/en/drugs/albuvirtide/patient
   Google Scholar
• Dong X. Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV: interim 48-week results from the randomized, controlled, phase 3, non-inferiority TALENT study. HIV Glasgow 2020; 23-26 Oct 2016, 2016; Virtual.
   Google Scholar
• Su B, Yao C, Zhao QX, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919–2927.
   PubMed Web of Science ®Google Scholar
• Firstwordpharma.org [Internet]. 2018 [ cited 2021 Feb 21]. Frontier Biotechnologies’ Aikening gains approval in China as first domestically developed HIV therapy. Available from: https://www.firstwordpharma.com/node/1570731
   Google Scholar
• Cihlar T. Lenacapavir (GS-6207): first Clinically Active Long-Acting Inhibitor of HIV Capsid. Oral presentation at: navigating To The Nucleus. CROI. Boston: Massachusetts; 2020 March 8–11.
   Google Scholar
• Segal-Maurer S. Potent Antiviral Activity Of Lenacapavir in Phase ⅔ in Heavily ART-Experienced PWH. Presented at: new Weapon against SARS-CoV-2 and HIV. CROI. Boston: Massachusetts; 2020 March 8–11.
   Google Scholar
• Grobler J. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Abstract presented at: drugs: from Discovery to Challenges in Clinical Use. CROI. Boston: Massachusetts; 2016 February 22–25.
   Google Scholar
• Maeda K, Desai DV, Aoki M, et al. Delayed emergence of HIV-1 variants resistant to 4ʹ-ethynyl-2-fluoro-2ʹ-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir Ther. 2014;19(2):179–189.
   PubMed Web of Science ®Google Scholar
• Schürmann D, Rudd DJ, Zhang S, et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV. 2020;7:164–172.
   PubMed Web of Science ®Google Scholar
• Molina JM. MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naïve adults with HIV-1 infection. Abstract presented at: recent developments in antiretroviral therapy. Mexico City: IAS; 2019 July 21–24.
   Google Scholar
• Molina JM. Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks. HIV Glasgow 2020;5-8 Oct 2020, 2020; Virtual.
   Google Scholar
• Orkin C. Analysis of protocol-defined virologic failure through week 96 from a phase 2 trial (011) of islatravir and doravirine in treatment-naïve adults with HIV-1 infected. HIV Glasgow 2020;5-8 Oct 2020, 2020; Virtual.
   Google Scholar
• Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019;25(4):547–553.
   PubMed Web of Science ®Google Scholar
• Promsote W, DeMouth ME, Almasri CG, et al. Anti-HIV-1 Antibodies: an Update. BioDrugs. 2020;34(2):121–132.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Wong -W-W, Tsai H-C, et al. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med. 2019;380(16):1535–1545.
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–861.
   PubMed Web of Science ®Google Scholar
• Crowell T, Colby D, Pinyakorn S, et al. VRC01 in Acutely Treated HIV-infected Adults: a Randomised, Double-blind, Placebo-controlled Trial. Lancet HIV. 2019;6(5):297–306.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Trotta MP, Shalev N, et al. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785–792. .
   PubMed Web of Science ®Google Scholar
• Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021;15:1–12.
   Google Scholar
• Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–e481.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–818.
   PubMed Web of Science ®Google Scholar
• Pepperrell T, Hill A, Moorhouse M, et al. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. J Virus Erad. 2020;6(2):70–73.
   PubMed Web of Science ®Google Scholar
• Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584(7822):614–618.
   PubMed Web of Science ®Google Scholar
• Margot RR, Parvangada P, Martin R, et al. Lenacapavir resistance analysis in a phase 1b clinical proof-of-concept study. HIV Glasgow 2020; 5-8 Oct 2020, 2020; Virtual.
   Google Scholar
• Matthews RP. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. Mexico City: Abstract presented at: Hot off the press: What’s new in HIV prevention. IAS; 2019 July 21–24.
   Google Scholar
• Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450–457.
   PubMed Web of Science ®Google Scholar
• Corey L, Gilbert PB, Juraska M, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021;384(11):1003–1014.
   PubMed Web of Science ®Google Scholar
• Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016;375(21):2037–2050.
   PubMed Web of Science ®Google Scholar
• Bar-On Y, Gruell H, Schoofs T, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24(11):1701–1707.
   PubMed Web of Science ®Google Scholar